MIRA INFORM REPORT

 

 

Report Date :           

09.06.2011

 

IDENTIFICATION DETAILS

 

Name :

TALECRIS BIOTHERAPEUTICS, INC.

 

 

Registered Office :

C/O The Corporation Trust Company, Corporation Trust Center 1209 Orange Street, Wilmington New Castle, De 19801  

 

 

Country :

United States 

 

 

Date of Incorporation :

09.12.2004

 

 

Com. Reg. No.:

3893562

 

 

Legal Form :

Corporation for Profit

 

 

Line of Business :

Biopharmaceutical Company

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

 

 

Payment Behaviour :

Unknown          

 

 

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – March 31st, 2011

 

Country Name

Previous Rating

                   (31.12.2010)                  

Current Rating

(31.03.2011)

United States 

a1

a1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 Bottom of Form

 

GEOPOLITICS - UNITED STATES

 

POLITICAL DATA

ECONOMIC DATA

Form of Government: Federal


Economic Risk: Nil

Currency: USD

Branch Situation: Stable

 

 

IDENTIFICATION

 

Ordered as:

Talecris Biotherapeuticals Inc

Address in the order:

P O Box 110526 79 TW Alexander Drive 4101 Research Commons RTP NC27709

Comments on data supplied:

The correct name of the company is TALECRIS BIOTHERAPEUTICS, INC.

Legal Name:

TALECRIS BIOTHERAPEUTICS, INC.

 

 

Legal Address

C/O THE CORPORATION TRUST COMPANY

CORPORATION TRUST CENTER 1209 ORANGE STREET

WILMINGTON NEW CASTLE

DE 19801 (registered agent\'s address)

Operative Address

4101 RESEARCH COMMONS, 79 TW ALEXANDER DRIVE

RESEARCH TRIANGLE PARK NC 27709

Telephone:

919-316-6300

Registration Number :

3893562

Fax:

919-316-6316

Legal Form:

Corporation for Profit

Email:

-

Registered in:

Delaware

Website:

www.talecris.com

Date Created:

2005

Manager:

LAWRENCE STERN - President

Date Incorporated:

December 9, 2004

Staff:

5,400 (group)

Stock:

N.A.

 

 

Value:

N.A.

Activity:

Biopharmaceutical company

 

 

BANKS

 

Name of the Bank

JPMORGAN CHASE BANK

Location                                   

1 CHASE SQ T-25 ROCHESTER  NY   14643

Name of the Bank

WACHOVIA BANK

Location                                   

1133 AVENUE OF THE AMERICAS NEW YORK  NY   10036

 

 

BUSINESS

 

HISTORY

 

Talecris Biotherapeutics was founded in 2005, building upon a nearly 70-year legacy in the plasma protein industry.

PRINCIPAL ACTIVITY

 

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas.

 

***IMPORTANT INFORMATION***

 

The subject company was acquired by Grifols SA on June 1st, 2011, and will be merged into the later.

 

Press articles:

 

- Grifols Announces the Completion of its Acquisition of Talecris and the Listing of its ADSs on NASDAQ

BARCELONA, Spain, June 3, 2011 /PRNewswire/ -- Grifols, S.A. (NASDAQ: GRFS) ("Grifols") a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain today announced that on June 1, 2011, Grifols completed its acquisition of Talecris Biotherapeutics Holdings Corp. ("Talecris"). In partial consideration for their shares, Talecris shareholders received Grifols non-voting shares that trade in the U.S. as Grifols ADSs. These new Grifols ADSs are listed on the NASDAQ Stock Exchange under the symbol "GRFS."

 

 

- Grifols Announces Combined Operations With Talecris to Begin a New Era as a Global Leader of Life-Saving Plasma Therapeutics

Combining Expertise to Bring Greater Benefit to Patients

RESEARCH TRIANGLE PARK, N.C., June 8, 2011 /PRNewswire via COMTEX/ -- (NASDAQ: GRFS) - Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain, today announced that it has officially begun to merge its operations with Talecris Biotherapeutics in order to function as one company, following its acquisition of Talecris on June 1. Through the acquisition, Grifols will build upon its 70-year legacy of creating life-saving medicines and products by incorporating Talecris' substantial experience and skill in producing plasma protein therapies.

[...]

Talecris will adopt the Grifols, Inc. name as the North American corporate subsidiary of Grifols, S.A., the Spanish holding company based in Barcelona, Spain.

Products/Services description:

 

Talecris produces 11 protein therapies that are derived from human plasma, a rich source of proteins that support healthy physical and neurologic function.

Therapies made from plasma are primarily used to replace or restore missing proteins among patients with rare diseases such as immune deficiencies, blood disorders and genetic emphysema.

Operations area:

 

National, International

Competitors:

 

- Baxter International Inc.

- CSL Behring, LLC

 

The subject employs 5,400 (group) employee(s)

LOCATION

Headquarters

 

101 RESEARCH COMMONS, 79 TW ALEXANDER DRIVE

RESEARCH TRIANGLE PARK NC 27709.

 

Talecris headquarters is located in the biotechnology hub of Research Triangle Park, N.C., USA.

Comments on location:

 

The company is incorporated in Delaware for tax purposes.

However, it is headquartered in North CArolina.

Branches:

 

Talecris’ primary manufacturing facility is located in Clayton, N.C., USA, with additional fractionation capacity and contract manufacturing provided by its facility in Melville, N.Y:

 

- 8368 US 70 West

Clayton, North Carolina 27520

USA

 

- 155 Duryea Road

Melville, NY 11747

USA

 

Other branches:

 

- The Evening Star Building

1101 Pennsylvania Avenue NW

Suite 600

Washington, DC 20004 USA

 

- R&D:

85 T.W. Alexander Drive

PO Box 110526

Research Triangle Park, NC 27709

USA



Shareholders - Manager - Related Companies

 

Listed at the stock exchange:

 

NO

Shareholders Parent Company(ies):

 

The company is owned by:

 

Talecris Biotherapeutics Holdings Corp.

PO Box 110526 4101 Research Commons 79 T. W. Alexander Drive

Research Triangle Park, NC 27709

United States

 

Talecris Biotherapeutics Holdings Corp. was publicly traded at the NASDAQ until June 2011.

 

On June 1, 2011, it was acquired by Grifols SA, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain.

 

Grifols SA is publicly traded at the NASDAQ (GRFS).

Management:

 

Thomas Glanzmann, Chairman of the Board, Grifols SA's US operations

Gregory Rich, CEO of Grifols' expanded U.S. operations that now include manufacturing facilities and corporate offices in North Carolina.

Victor Grifols, President and CEO of Grifols SA in Spain.

Related Companies:

 

Talecris Biotherapeutics, GmbH (Germany)

Talecris Biotherapeutics Ltd. (Canada)

Talecris Biotherapeutics (UAE)

Talecris Plasma Resources (USA)



Financials - COMMERCIAL TRENDS AND FORECAST

 

As a private company the subject does not publish any financial statements.

Legal Fillings

 There are several UCC files listed with the Secretary of State of North Carolina.

 

The last annual report was filed on 1/26/2011.

 

There are no legal filings listed with the District Court.

 

THE COMPANY IS NOT LISTED ON THE OFAC LIST.*

 

 

For information:

 

* The Specially Designated Nationals (SDN) List is a publication of OFAC which lists individuals and organizations with whom United States citizens and permanent residents are prohibited from doing business.

 

** The Uniform Commercial Code (UCC) is one of a number of uniform acts that have been promulgated in conjunction with efforts to harmonize the law of sales and other commercial transactions in all 50 states within the United States of America. 

 

The UCC deals primarily with transactions involving personal property (movable property), not real property (immovable property).

 

It allows a creditor to notify other creditors about a debtor’s assets used as collateral for a secured transaction by filing a public notice (financing statement) with a particular filing office.

 

The Uniform Commercial Code Bureau files and maintains on financial obligations (including IRS liens) incurred by individuals (in business as a sole proprietor), business entities and corporations.

 

 




 Final Opinion

 

The subject started operating in 2005.

 

It was acquired on June 1, 2011 by a Spanish competitor, Grifols, SA, which announced on June 8 that it will merge Talecris's operations into its US operations.

 

For this reason, we suggest caution, as the subject is bound to disappear by merger.

The timing of the merger has not been released yet.

 

We suggest monitoring the evolution withing the next 6 months.

 



APPENDIX

 

Comments

 

We were transferred to several departments, but nobody would comment or answer our questions.

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.44.61

UK Pound

1

Rs.73.28

Euro

1

Rs.65.47

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.